SAN

79.03

+0.22%↑

UCB

228.2

-3.51%↓

SHL.DE

35.29

-0.82%↓

ARGX

666.2

-1.54%↓

VIE

35.78

+0.56%↑

SAN

79.03

+0.22%↑

UCB

228.2

-3.51%↓

SHL.DE

35.29

-0.82%↓

ARGX

666.2

-1.54%↓

VIE

35.78

+0.56%↑

SAN

79.03

+0.22%↑

UCB

228.2

-3.51%↓

SHL.DE

35.29

-0.82%↓

ARGX

666.2

-1.54%↓

VIE

35.78

+0.56%↑

SAN

79.03

+0.22%↑

UCB

228.2

-3.51%↓

SHL.DE

35.29

-0.82%↓

ARGX

666.2

-1.54%↓

VIE

35.78

+0.56%↑

SAN

79.03

+0.22%↑

UCB

228.2

-3.51%↓

SHL.DE

35.29

-0.82%↓

ARGX

666.2

-1.54%↓

VIE

35.78

+0.56%↑

Search

Fagron

Uždarymo kaina

SektoriusSveikatos priežiūra

23.6 -0.42

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.4

Max

23.75

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-99K

45M

Pardavimai

-98K

476M

P/E

Sektoriaus vid.

19.557

60.328

Dividendų pajamingumas

1.64

Pelno marža

9.55

Darbuotojai

4,193

EBITDA

11M

98M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.64%

2.24%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

149M

1.8B

Ankstesnė atidarymo kaina

24.02

Ankstesnė uždarymo kaina

23.6

Naujienos nuotaikos

By Acuity

50%

50%

157 / 348 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-27 23:15; UTC

Svarbiausios naujienos

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

2026-04-27 23:08; UTC

Uždarbis
Pagrindinės rinkos jėgos

LendingClub Shares Gain on 1Q Profit, Revenue Beat

2026-04-27 23:58; UTC

Uždarbis

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-27 23:58; UTC

Uždarbis

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

2026-04-27 23:56; UTC

Uždarbis

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

2026-04-27 23:56; UTC

Uždarbis

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

2026-04-27 23:48; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

2026-04-27 23:42; UTC

Rinkos pokalbiai

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

2026-04-27 23:34; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

2026-04-27 23:30; UTC

Rinkos pokalbiai

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

2026-04-27 23:08; UTC

Rinkos pokalbiai

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

2026-04-27 23:02; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-27 23:02; UTC

Rinkos pokalbiai

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

2026-04-27 22:42; UTC

Rinkos pokalbiai

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

2026-04-27 22:10; UTC

Uždarbis

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

2026-04-27 21:56; UTC

Uždarbis

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

2026-04-27 21:55; UTC

Uždarbis

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

2026-04-27 21:55; UTC

Uždarbis

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

2026-04-27 21:44; UTC

Uždarbis

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

2026-04-27 21:43; UTC

Uždarbis

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

2026-04-27 21:41; UTC

Uždarbis

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

2026-04-27 21:41; UTC

Uždarbis

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

2026-04-27 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-27 20:39; UTC

Uždarbis

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

157 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat